Consequently, the Cohn process is not able to meet worldwide demand. The
complex steps and regulations required to collect donated plasma and complete the
highly technical, innovative manufacturing processes that ultimately result in a final
therapy result in long intervals between donation and final product release —
between seven and nine months. This sets the production of plasma protein
therapies apart from other biologics whose manufacturing processes are much
more truncated and whose direct manufacturing costs are a significantly smaller
portion of the overall cost. Hence the need for a platform that increases the
amount of proteins extracted from plasma (yield) and identifies additional
enhancements that can create even more effective therapies.
4 ProMetic’s Plasma Process Improves Commercial Viability
ProMetic Life Sciences (PLI) PPPSTM uses a chromatographic approach to plasma
fractionation which significantly reduces losses incurred using the more
conventional Cohn precipitation process. In PPPSTM, each protein is removed from
the plasma by a specific ProMetic Mimetic Ligand™ adsorbent and subsequently
purified in a side stream. The removal sequence has been optimised to give
exceptionally high protein recoveries at unprecedented activity levels and allows
the recovery of new biotherapeutics as they are discovered and identified.
On Wednesday, PLI announced that the recovery yield for AAT achieved with its
PPPS™ now represents a 220% improvement over the existing industry average
compared with 170% previously reported.